NCT05690802 The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV
| NCT ID | NCT05690802 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Nausea and Vomiting |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,060 participants |
| Start Date | 2022-05-16 |
| Primary Completion | 2027-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,060 participants in total. It began in 2022-05-16 with a primary completion date of 2027-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the applicable population, clinical medication and clinical benefits of Palonosetron Hydrochloride Capsules were analyzed.
Eligibility Criteria
Inclusion Criteria: * For patients with malignant tumors who can accept chemotherapy, the disease type is not limited. The specific chemotherapy scheme is the chemotherapy scheme with moderate risk of vomiting (for the risk level of vomiting, refer to the 2019 CSCO anti-tumor treatment related nausea and vomiting prevention and treatment guidelines); * 18-75 years old, KPS score ≥ 70, and the expected survival time is more than 3 months; * Before treatment, ECG, blood routine test, liver and kidney functions and electrolytes were basically normal; * All patients signed the informed consent form Exclusion Criteria: * Patients with chemotherapy contraindications, patients allergic to 5-HT3RA, pregnant women and lactating women; * People with digestive tract obstruction; Patients with serious heart disease, liver and kidney disease and metabolic disorder; Patients suffering from epilepsy or using psychotropic and sedative drugs; * Used antiemetic drugs or chemicals within 24 hours.Those who have vomited before treatment may have brain metastasis, intracranial hypertension, gastrointestinal obstruction, psychological abnormalities, etc.Patients with factors causing nausea and vomiting.
Contact & Investigator
Liu Hong, master
STUDY CHAIR
Air Force Military Medical University, China
Frequently Asked Questions
Who can join the NCT05690802 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Nausea and Vomiting. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05690802 currently recruiting?
Yes, NCT05690802 is actively recruiting participants. Contact the research team at hongliu1@fmmu.edu.cn for enrollment information.
Where is the NCT05690802 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT05690802 clinical trial?
NCT05690802 is sponsored by Xijing Hospital. The principal investigator is Liu Hong, master at Air Force Military Medical University, China. The trial plans to enroll 1,060 participants.